NCT05404529View on ClinicalTrials.gov

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 29, 2022

Primary Completion Date

January 24, 2023

Study Completion Date

January 24, 2023

Conditions
Hepatic Impairment
Interventions
DRUG

Tavapadon

Oral tablets

Trial Locations (3)

32809

Orlando, Florida, Orlando

33014

Miami, Florida, Miami

78215

San Antonio, Texas, San Antonio

Sponsors
All Listed Sponsors
lead

Cerevel Therapeutics, LLC

INDUSTRY

NCT05404529 - To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function | Biotech Hunter | Biotech Hunter